NCM
ARQT icon

Nearwater Capital Markets’s Arcutis Biotherapeutics ARQT Stock Holding History

Nearwater Capital Markets’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.8M Sell
486,700
-120,600
-20% -$2.81M 0.22% 78
2026
Q1 		$14.3M Sell
607,300
-7,700
-1% -$197K 0.34% 62
2025
Q4 		$17.9M Buy
+615,000
New +$15.7M 0.31% 61

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Nearwater Capital Markets's ARQT Position: Q2 2026 in Review

Nearwater Capital Markets reduced its Arcutis Biotherapeutics (ARQT) stake by 20% in Q2 2026, selling an estimated $2.81M and leaving 486,700 shares worth $12.8M. The position accounts for 0.22% of the portfolio, ranked #78.

Nearwater Capital Markets first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. The position peaked at $17.9M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Nearwater Capital Markets held 486,700 shares of Arcutis Biotherapeutics worth $12.8M as of Q2 2026.
  • Nearwater Capital Markets sold 120,600 Arcutis Biotherapeutics shares in Q2 2026, an estimated $2.81M.
  • Arcutis Biotherapeutics made up 0.22% of Nearwater Capital Markets's portfolio in Q2 2026, its #78 holding.
  • Nearwater Capital Markets first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • Nearwater Capital Markets's Arcutis Biotherapeutics position peaked at $17.9M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Nearwater Capital Markets's 13F filing for Q2 2026, filed 14 Aug 2026.